Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

NOVANTA INC
Next earnings Aug 3, 2026 · consensus $0.85 EPS, $268M rev
Last earnings +1.2% on 2026-05-11
Quality acquisitive photonics/medical-tech compounder with a fortress balance sheet, but declining GAAP earnings against a 105x P/E.
Sources: SEC EDGAR (CIK 0001076930, latest 10-Q filed 2026-05-11) · EODHD · analysis by claude-code · as of 6/21/2026, 8:58:09 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
Middling fundamentals and a rich price (~93% above fair value) leave little margin of safety — a wait-and-see.
Novanta designs precision photonics, vision, and motion technologies embedded in medical, life-science, and advanced-industrial/automation equipment — a high-quality, recurring, design-in franchise built through serial acquisitions. The balance sheet is excellent and improved sharply in FY2025: cash more than tripled to $381M, long-term debt fell 48.4% to $213M, equity jumped 76.2% to $1.31B, and leverage is a low 0.37x liabilities/equity. Gross margin is a healthy 44.4%, R&D is sustained at $95.5M, and the company continues to repurchase stock ($39.3M, up 292.8%).
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $707M | $861M | $882M | $949M | $981M |
| Gross profit | $300M | $378M | $400M | $422M | $435M |
| Operating income | $64.1M | $103M | $110M | $111M | $94.0M |
| Net income | $50.3M | $74.1M | $72.9M | $64.1M | $53.8M |
| Diluted EPS | $1.41 | $2.06 | $2.02 | $1.77 | $1.47 |
| Net margin | 7.1% | 8.6% | 8.3% | 6.8% | 5.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1 buy · 1 member · last 180d
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1482 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 13 sales
| 2026-06-02 | Glastra Matthijs Chief Executive Officer | Sell | 38.00 @ $164.61 | $6.26K |
| 2026-06-02 | Glastra Matthijs Chief Executive Officer | Sell | 500.00 @ $166.19 | $83.1K |
| 2026-06-02 | Glastra Matthijs Chief Executive Officer | Sell | 1.42K @ $167.68 | $238K |
| 2026-06-02 | Glastra Matthijs Chief Executive Officer | Sell | 2.84K @ $168.76 | $479K |
| 2026-06-02 | Glastra Matthijs Chief Executive Officer | Sell | 1.30K @ $169.76 | $221K |
| 2026-06-02 | Glastra Matthijs Chief Executive Officer | Sell | 400.00 @ $171.28 | $68.5K |
| 2026-05-12 | Glastra Matthijs Chief Executive Officer | Sell | 5.08K @ $150.00 | $762K |
| 2026-05-12 | Glastra Matthijs Chief Executive Officer | Sell | 2.42K @ $151.34 | $366K |
| 2026-05-05 | Glastra Matthijs Chief Executive Officer | Sell | 4.28K @ $130.59 | $558K |
| 2026-05-05 | Glastra Matthijs Chief Executive Officer | Sell | 1.02K @ $131.75 | $135K |
| 2026-05-05 | Glastra Matthijs Chief Executive Officer | Sell | 1.18K @ $132.51 | $156K |
| 2026-05-05 | Glastra Matthijs Chief Executive Officer | Sell | 23.00 @ $133.27 | $3.07K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.